Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364325 | 0.79 | TSHR (0.41) | KMT2APOLBTSHRSIGMAR1MAOB | |
| SCHEMBL1364229 | 0.78 | KMT2A (0.40) | KMT2ATSHR | |
| SCHEMBL1364740 | 0.73 | KMT2A (0.40) | KMT2ATSHRDRD2 | |
| SCHEMBL8552803 | 0.71 | KDM1A (0.45) | KMT2AMEN1POLB | |
| SCHEMBL9411283 | 0.69 | GID4 (0.59) | KMT2AMEN1SMN1; SMN2POLB | |
| SCHEMBL6392691 | 0.68 | KMT2A (0.70) | KMT2A | |
| SCHEMBL8982764 | 0.68 | TBXA2R (0.49) | KMT2AMEN1DRD3 | |
| SCHEMBL1364874 | 0.66 | KMT2A (0.40) | KMT2AALDH1A1 | |
| SCHEMBL6392485 | 0.64 | KDM4C (0.49) | KMT2A | |
| SCHEMBL12635434 | 0.64 | SLC6A3 (0.55) | KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, HRH3 | KMT2A 817/4885MEN1 1977/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.